Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sera PrognosticsSERA -5.96%69 5-Day RSI is 44.56 as of Jul. 26, 2026. GuruFocus rates SERA with a GF Score™ of 69/100 and a GF Value™ of $1.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 862 Medical Devices & Instruments companies, Sera Prognostics ranks worse than 58.35% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-26), Sera Prognostics's 5-Day RSI is 44.56.
The industry rank for Sera Prognostics's 5-Day RSI or its related term are showing as below:
SERA's 5-Day RSI is ranked worse than 58.35% of 862
companies
in the Medical Devices & Instruments industry
Industry Median: 40.195
vs SERA: 44.56
Sera Prognostics (NAS:SERA) 5-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Sera Prognostics 5-Day RSI Related Terms
SERA vs LNSR, ECOR, SNWV: 5-Day RSI Comparison
For the Medical Devices subindustry, Sera Prognostics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sera Prognostics 5-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sera Prognostics's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Sera Prognostics's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sera Prognostics (SERA) has a 5-Day RSI of 44.56 as of Jul. 26, 2026. According to the industry distribution chart, Sera Prognostics ranks #503 out of 862 companies in the Medical Devices & Instruments industry, placing it in the top 58.4%.
Is Sera Prognostics' 5-Day RSI too high?
Sera Prognostics' current 5-Day RSI is 44.56. The Medical Devices & Instruments industry median 5-Day RSI is 40.20. Sera Prognostics' value of 44.56 is 10.9% above this industry median. Based on the distribution chart, Sera Prognostics ranks #503 out of 862 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sera Prognostics has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sera Prognostics' 5-Day RSI compare to LNSR and ECOR?
According to the Medical Devices & Instruments industry distribution chart, Sera Prognostics ranks #503 out of 862 companies for 5-Day RSI. This places Sera Prognostics in the lower half of its industry. The industry median 5-Day RSI is 40.20. Sera Prognostics' value of 44.56 is 10.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Medical Devices & Instruments company?
The median 5-Day RSI among Medical Devices & Instruments companies is 40.20, based on 862 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sera Prognostics's current 5-Day RSI of 44.56 is 10.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 5-Day RSI is 40.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sera Prognostics's current 5-Day RSI is 44.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sera Prognostics stock overvalued right now?
Based on GuruFocus' analysis, Sera Prognostics (SERA) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.83, compared to a current price of $2.05 — trading 12% above its estimated fair value. The current 5-Day RSI is 44.56 and 10.9% above the Medical Devices & Instruments industry median of 40.20. Sera Prognostics' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Sera Prognostics (SERA), the current 5-Day RSI is 44.56 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sera Prognostics (SERA) Overvalued in 2026?
Based on GuruFocus' analysis, Sera Prognostics stock appears to be overvalued.
The current stock price of $2.05 is trading 12% above its estimated GF Value™ of $1.83.
GuruFocus considers Sera Prognostics to be Modestly Overvalued.
Key valuation signals for SERA:
5-Day RSI: 44.56
GF Value™: $1.83 vs. price of $2.05 (12% above fair value)
Industry Position: 10.9% above the Medical Devices & Instruments median (#503 of 862)
No single metric tells the full story. See the SERA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
69GF Score
Get the complete analysis for SERA
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SERA has been successfully added to your 
